Cargando…

Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output

BACKGROUND: Glucagon-like peptide-1 (GLP-1) and its based agents improve glycemic control. Although their attenuating effect on hepatic glucose output has drawn our attention for decades, the potential mechanisms remain unclear. METHODS: Cytokine array kit was used to assess cytokine profiles in db/...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Junling, Yang, Kun, Yang, Jin, Xiao, Wenhua, Le, Yunyi, Yu, Fei, Gu, Liangbiao, Lang, Shan, Tian, Qing, Jin, Tianru, Wei, Rui, Hong, Tianpei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Research paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443026/ https://www.ncbi.nlm.nih.gov/pubmed/30827929 http://dx.doi.org/10.1016/j.ebiom.2019.02.037

Ejemplares similares

Antagonistic Glucagon Receptor Antibody Promotes α-Cell Proliferation and Increases β-Cell Mass in Diabetic Mice
por: Wei, Rui, et al.
Publicado: (2019)

Glucagon receptor antagonist upregulates circulating GLP-1 level by promoting intestinal L-cell proliferation and GLP-1 production in type 2 diabetes
por: Lang, Shan, et al.
Publicado: (2020)

Pancreatic alpha cell glucagon–liver FGF21 axis regulates beta cell regeneration in a mouse model of type 2 diabetes
por: Cui, Xiaona, et al.
Publicado: (2022)

Pro-α-cell-derived β-cells contribute to β-cell neogenesis induced by antagonistic glucagon receptor antibody in type 2 diabetic mice
por: Cui, Xiaona, et al.
Publicado: (2022)

Glucagon Acting at the GLP-1 Receptor Contributes to β-Cell Regeneration Induced by Glucagon Receptor Antagonism in Diabetic Mice
por: Wei, Tianjiao, et al.
Publicado: (2023)

The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs—Therapeutic potential exploration in lung injury
por: Pang, Juan, et al.
Publicado: (2022)

Fibroblast growth factor 21 and dietary interventions: what we know and what we need to know next
por: Jin, Tianru
Publicado: (2022)

Role of Fibroblast Growth Factor 21 in Biology of Glucagon
por: Berglund, Eric D., et al.
Publicado: (2013)

Association of Time in Range with Endothelial Injury in Patients with Type 2 Diabetes Treated with Exenatide
por: Le, Yunyi, et al.
Publicado: (2022)

Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions
por: Habegger, Kirk M., et al.
Publicado: (2013)

Effects of Glucagon-Like Peptide-1 Analogue and Fibroblast Growth Factor 21 Combination on the Atherosclerosis-Related Process in a Type 2 Diabetes Mouse Model
por: Kim, Jin Hee, et al.
Publicado: (2021)

The effect of endogenously released glucose, insulin, glucagon-like peptide 1, ghrelin on cardiac output, heart rate, stroke volume, and blood pressure
por: Hlebowicz, Joanna, et al.
Publicado: (2011)

Glucagon Like Peptide-1-Induced Glucose Metabolism in Differentiated Human Muscle Satellite Cells Is Attenuated by Hyperglycemia
por: Green, Charlotte J., et al.
Publicado: (2012)

Hepatic hormone FGF21 and its analogues in clinical trials
por: Shao, Weijuan, et al.
Publicado: (2022)

Human Monoclonal Antibodies against Glucagon Receptor Improve Glucose Homeostasis by Suppression of Hepatic Glucose Output in Diet-Induced Obese Mice
por: Kim, Wook-Dong, et al.
Publicado: (2012)

Pregnancy glucagon-like peptide 1 predicts insulin but not glucose concentrations
por: Jones, Danielle L., et al.
Publicado: (2023)

Unlocking the Therapeutic Potential of Glucagon-Like Peptide-1 Analogue and Fibroblast Growth Factor 21 Combination for the Pathogenesis of Atherosclerosis in Type 2 Diabetes
por: Son, Jang Won
Publicado: (2021)

Association of glucagon‐like peptide‐1 receptor‐targeted imaging probe with in vivo glucagon‐like peptide‐1 receptor agonist glucose‐lowering effects
por: Murakami, Takaaki, et al.
Publicado: (2020)

Computational Peptide Design Cotargeting Glucagon and Glucagon-like Peptide-1 Receptors
por: Vishnoi, Shubham, et al.
Publicado: (2023)

Microbially produced glucagon-like peptide 1 improves glucose tolerance in mice
por: Arora, Tulika, et al.
Publicado: (2016)

Ghrelin and glucagon-like peptide-1 according to body adiposity and glucose homeostasis
por: Lopes, Karynne Grutter, et al.
Publicado: (2023)

Establishment of a Refined Oral Glucose Tolerance Test in Pigs, and Assessment of Insulin, Glucagon and Glucagon-Like Peptide-1 Responses
por: Manell, Elin, et al.
Publicado: (2016)

Glucagon‐like peptide‐1 and glucose‐dependent insulinotropic peptide: effects alone and in combination on insulin secretion and glucose disappearance in mice
por: Pacini, Giovanni, et al.
Publicado: (2017)

Glucose-sensing glucagon-like peptide-1 receptor neurons in the dorsomedial hypothalamus regulate glucose metabolism
por: Huang, Zhaohuan, et al.
Publicado: (2022)

Glucagon-like peptide receptor agonists attenuate advanced glycation end products-induced inflammation in rat mesangial cells
por: Chang, Jui-Ting, et al.
Publicado: (2017)

Stability of glucagon-like peptide 1 and glucagon in human plasma
por: Wewer Albrechtsen, Nicolai J, et al.
Publicado: (2015)

High Glucose Attenuates Cardioprotective Effects of Glucagon-Like Peptide-1 Through Induction of Mitochondria Dysfunction via Inhibition of β-Arrestin-Signaling
por: Pan, Xietian, et al.
Publicado: (2021)

Arcuate Glucagon-Like Peptide 1 Receptors Regulate Glucose Homeostasis but Not Food Intake
por: Sandoval, Darleen A., et al.
Publicado: (2008)

Mechanisms underlying glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 secretion
por: Reimann, Frank, et al.
Publicado: (2016)

Carbohydrate‐induced secretion of glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1
por: Seino, Yusuke, et al.
Publicado: (2016)

Correction: Glucagon-like peptide receptor agonists attenuate advanced glycation end products-induced inflammation in rat mesangial cells
por: Chang, Jui-Ting, et al.
Publicado: (2023)

Subthreshold α (2)-Adrenergic Activation Counteracts Glucagon-Like Peptide-1 Potentiation of Glucose-Stimulated Insulin Secretion
por: Pan, Minglin, et al.
Publicado: (2011)

Glucagon-like peptide-1 attenuates diabetes-associated osteoporosis in ZDF rat, possibly through the RAGE pathway
por: Cheng, Yanzhen, et al.
Publicado: (2022)

Fibroblast growth factor-21 is required for weight loss induced by the glucagon-like peptide-1 receptor agonist liraglutide in male mice fed high carbohydrate diets
por: Le, Thao D.V., et al.
Publicado: (2023)

Glucagon-Like Peptide-1 Receptor Agonist and Glucagon Increase Glucose-Stimulated Insulin Secretion in Beta Cells via Distinct Adenylyl Cyclases
por: Lee, Young-Sun, et al.
Publicado: (2018)

The glucagon‐like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents
por: Vallöf, Daniel, et al.
Publicado: (2015)

Glucagon-Like Peptide 1 Attenuates Lipotoxicity-Induced Islet Dysfunction in ApoE(–/–) Mice
por: Liu, Fuqiang, et al.
Publicado: (2020)

Glucagon-Like Peptide 1 Receptor Activation Augments Cardiac Output and Improves Cardiac Efficiency in Obese Swine After Myocardial Infarction
por: Sassoon, Daniel J., et al.
Publicado: (2017)

Glucagon-like peptide-1 and glucagon-like peptide-2 regulation during human liver regeneration
por: Ammann, Markus, et al.
Publicado: (2023)

Impaired Secretion of Total Glucagon-like Peptide-1 in People with Impaired Fasting Glucose Combined Impaired Glucose Tolerance
por: Zhang, Fang, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_lbnmj1mk1e6sfdt93dfoucmhoo